1. Japan Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Japan Tissue Engineering Co., Ltd.

Japan Tissue Engineering Co., Ltd.

TTSE:7774
723.00
JPY
-27.00
(-3.60%)
18.56BMarket Cap
Oct 30Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
27.45
34.85
35.26
52.61
55.94
58.06
56.88
55.59
51.8
50.05
61.91
60.46
53.74
- -
Basic EPS, GAAP
-22.54
-18.21
-16.79
6.81
5.61
-8.21
-7.07
-11.49
-12.26
-17.96
3.53
-6.29
-18.09
- -
Free Cash Flow per Basic Share
-27.11
-33.79
-14.96
0.77
14.78
-11.55
-4.33
-11.67
-8.43
-19.67
0.02
-5.97
-13.93
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
58.77
206.93
190.18
197.21
203.19
194.98
187.91
176.42
164.16
146.2
149.73
143.44
125.35
143.44
Tangible Book Value per Share
57.48
205.74
188.99
196.28
202.62
194.52
187.66
176.01
163.27
143.9
147.2
141.06
124.11
141.06
Basic Weighted Avg Shares
37
38
41
41
41
41
41
41
41
41
41
41
41
41
Sales/Revenue/Turnover
1,008
1,321
1,431
2,135
2,272
2,358
2,310
2,258
2,103
2,032
2,514
2,455
2,183
- -
Operating Margin (%)
-101.72
-52.06
-50.5
14.63
9.31
-14.83
-10.18
-20.68
-23.68
-35.82
5.75
-9.71
-25.17
- -
Depreciation Expense
88
86
136
113
116
120
124
128
125
131
134
158
157
- -
Net Income, GAAP
-828
-691
-682
276
228
-333
-287
-467
-498
-729
143
-255
-735
- -
Effective Tax Rate (%)
- -
- -
- -
10.88
- -
- -
- -
- -
- -
- -
2.61
- -
- -
- -
Profit Margin (%)
-82.12
-52.25
-47.63
12.94
10.03
-14.13
-12.43
-20.67
-23.67
-35.88
5.69
-10.4
-33.66
- -
Working Capital
1,372
6,327
4,011
4,572
6,360
6,228
6,033
5,626
5,049
4,300
4,466
4,188
3,622
4,188
LT Debt
437
19
15
8
3
3
2
1
- -
- -
- -
- -
- -
- -
Total Equity
2,163
8,397
7,718
8,005
8,251
7,918
7,631
7,164
6,666
5,937
6,080
5,825
5,090
5,825
Return on Invested Capital (%)
- -
- -
- -
3.52
- -
- -
- -
- -
- -
- -
2.33
- -
- -
- -
Return on Capital (%)
- -
- -
- -
3.51
- -
- -
- -
- -
- -
- -
2.38
- -
- -
- -
Return on Common Equity (%)
-36.88
-13.08
-8.46
3.51
2.8
-4.12
-3.69
-6.31
-7.2
-11.57
2.38
-4.29
-13.46
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'25
Sep'25
Mar'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
41
41
41
Market Capitalization
28,711
20,792
18,559

Working Capital

JPY

•

in mil. unless spec.
Jun'25
Sep'25
Mar'25
Total Current Assets
- -
4,895
4,825
Cash, Cash Equivalents & STI
- -
4,037
3,885
Accounts Receivable, Net
- -
485
544
Inventories
- -
188
182
Total Current Liabilities
- -
590
637
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.93%
-6.46%
-12.61%
Free Cash Flow
-2,413.99%
-5,157.24%
133.54%
Net Income, GAAP
-51.26%
-31.4%
187.79%
Sales/Revenue/Turnover
5.51%
0.01%
-11.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2,455
2026
- -
- -
- -
- -
2,183
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
-6.29
2026
- -
- -
- -
- -
-18.09
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kazuto Yamada
Full Time Employees
200
Sector
Health services
Industry
Medical/Nursing services
Address
6-209-1 Miyakitadori Gamagori AI Japan 443-0022
IPO Date
Dec 21, 2007
Website
jpte.co.jp
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Japan Tissue Engineering Co., Ltd. (7774.T) develops, manufactures and commercializes regenerative medicine products using tissue engineering technology in Japan. The company offers autologous cultured epidermis (JACE) for severe burns, congenital giant pigmented nevus and epidermolysis bullosa; autologous cultured cartilage (JACK) for traumatic cartilage defects, osteochondritis dissecans and knee osteoarthritis; autologous cultured corneal epithelium (EYE-01M) and autologous cultured oral mucosal epithelium (Ocural) for corneal epithelial stem cell deficiency; and autologous cultured epidermis maintaining melanocytes for vitiligo. It also provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, regulatory consulting and contract manufacturing of specific cell-processed products through its regenerative medicine outsourcing segment; and human cultured tissues for research purposes via its research and development support segment. Founded in 1999 and headquartered in Gamagori, Aichi, the company operates production facilities in Gamagori and serves medical institutions primarily in Japan as a subsidiary within the Teijin Group since 2021. Recent developments include expansion of JACK indications to knee osteoarthritis in May 2025; selection for government subsidies in July 2025 to expand regenerative medicine CDMO operations alongside Teijin Regenet Co.; a capital and business alliance with VCCT Inc. in December 2024 to accelerate commercialization of iPS cell-based retinal products; a research collaboration agreement with Sysmex Corporation in March 2025 on sterility testing for regenerative medicine and cell therapy; and insurance coverage for autologous cultured epidermis with melanocytes for vitiligo starting October 2024.